Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2006/02/01
-
Journal
-
Indian UGC (journal)
-
Refrences150
-
Citations1,711
-
Geoffrey C. Farrell
-
Claire Z. Larter
Abstract
Cite
Farrell, Geoffrey C., and Claire Z. Larter. “Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis”. Hepatology, vol. 43, no. Supplement 1, 2006, pp. S99-S112, https://doi.org/10.1002/hep.20973.
Farrell, G. C., & Larter, C. Z. (2006). Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis. Hepatology, 43(Supplement 1), S99-S112. https://doi.org/10.1002/hep.20973
Farrell, Geoffrey C., and Claire Z. Larter. “Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis”. Hepatology 43, no. Supplement 1 (2006): S99-S112. https://doi.org/10.1002/hep.20973.
Farrell GC, Larter CZ. Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis. Hepatology. 2006;43(Supplement 1):S99-S112.
Journal Categories
Medicine
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the digestive system
Gastroenterology
Medicine
Medicine (General)
You May Also Like
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
- Macrophages: Master Regulators of Inflammation and Fibrosis
- Hsp27 Inhibits Cytochrome c-Mediated Caspase Activation by Sequestering Both Pro-caspase-3 and Cytochrome c
- Identification of IL-10 and TGF-β Transcripts Involved in the Inhibition of T-Lymphocyte Proliferation During Cell Contact With Human Mesenchymal Stem Cells
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Obesity and hepatocellular carcinoma | Gastroenterology |
| 266 | 2004 |
| Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? | Journal of Hepatology |
| 108 | 2006 |
Mitochondrial Dysfunction and Type 2 Diabetes | Science |
| 1,428 | 2005 |
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population | American Journal of Physiology-Endocrinology and Metabolism |
| 1,114 | 2005 |
| Hepatic CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling | Journal of Biological Chemistry |
| 2005 |
Refrences Analysis
The category
Medicine: Medicine (General) 84
is the most frequently represented among the references in this article. It primarily includes studies from Gastroenterology and Journal of Hepatology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study | JGH Open |
| 2024 | |
| Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease | Hepatology International |
| 2024 | |
| Oral Supplementation of Phosphatidylcholine Attenuates the Onset of a Diet-Induced Metabolic Dysfunction–Associated Steatohepatitis in Female C57BL/6J Mice | Cellular and Molecular Gastroenterology and Hepatology |
| 1 | 2024 |
| Cucurbitacin B ameliorates AKT-driven fatty liver disease in mice by suppressing AKT/mTORC1 and LXRα/SREBP1 lipogenic pathways | Journal of Functional Foods |
| 2024 | |
| Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease | Journal of the Formosan Medical Association |
| 2024 |
Citations Analysis
The category
Medicine: Medicine (General) 854
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled CuZn-SOD Deficiency Causes ApoB Degradation and Induces Hepatic Lipid Accumulation by Impaired Lipoprotein Secretion in Mice and was published in 2006. The most recent citation comes from a 2024 study titled Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. This article reached its peak citation in 2014, with 137 citations. It has been cited in 681 different journals, 22% of which are open access. Among related journals, the PLOS ONE cited this research the most, with 60 citations. The chart below illustrates the annual citation trends for this article.